Trade and other liabilities, and provisions - Narrative (Details) - EUR (€) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Jun. 21, 2022 |
|
| Business combinations during the period | ||
| Fair value Adjustment Contingent consideration Payable related to the acquisition of cellpoint | € 21,760,000 | |
| Other provisions related to the small molecules business | 45,499,000 | |
| Cell Point Acquisition | ||
| Business combinations during the period | ||
| Fair value of contingent consideration | € 20,600,000 | |
| Contingent consideration on certain development milestone | 20,000,000 | |
| Contingent consideration on regulatory milestone | 30,000,000 | |
| Contingent consideration on sales based milestone | 50,000,000 | |
| Fair value Adjustment Contingent consideration Payable related to the acquisition of cellpoint | € 21,800,000 | |
| Cell Point Acquisition | Maximum | ||
| Business combinations during the period | ||
| Additional contingent consideration | € 100,000,000 |